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Abstract
Background: Cluster randomized trials are common in health research in low- and middle-income countries raising
issues that challenge interpretation of standard ethical guidelines. While the Ottawa Statement on the ethical
design and conduct of cluster randomized trials provides guidance for researchers and research ethics committees,
it does not explicitly focus on low- and middle-income settings.
Main body: In this paper, we use the lens of the Ottawa Statement to analyze two cluster randomized trials
conducted in low- and middle-income settings in order to identify gaps or ethical issues requiring further analysis
and guidance. The PolyIran trial was a parallel-arm, cluster trial examining the effectiveness of a polypill for
prevention of cardiovascular disease in Golestan province, Iran. The PASTAL trial was an adaptive, multistage,
parallel-arm, cluster trial evaluating the effect of incentives for human immunodeficiency virus self-testing and
follow-up on male partners of pregnant women in Malawi. Through an in-depth case analysis of these two studies
we highlight several issues in need of further exploration. First, standards for verbal consent and waivers of consent
require methods for operationalization if they are to be employed consistently. Second, the appropriate choice of a
control arm remains contentious. Particularly in the case of implementation interventions, locally available care is
required as the comparator to address questions of comparative effectiveness. However, locally available care might
be lower than standards set out in national guidelines. Third, while the need for access to effective interventions
post-trial is widely recognized, it is often not possible to guarantee this upfront. Clarity on what is required of
researchers and sponsors is needed. Fourth, there is a pressing need for ethics education and capacity building
regarding cluster randomized trials in these settings.
Conclusion: We identify four issues in cluster randomized trials conducted in low- and middle-income countries for
which further ethical analysis and guidance is required.
Keywords: Cluster randomized trial, Research ethics, Ethics, Low- and middle-income countries, Informed consent,
Equipoise, Post-trial access, Research ethics committee
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Introduction
Cluster randomized trials (CRTs) are an increasingly im-
portant method used in health research, including re-
search conducted in low- and middle-income countries
(LMICs). In CRTs, intact social units, or ‘clusters,’ are
randomly allocated to intervention and control condi-
tions, and outcomes are usually collected on individual
cluster members [1]. Clusters are diverse and include
whole communities, neighborhoods, hospitals, clinics
and schools. A random sample of CRTs published be-
tween 2000 and 2008 revealed that 15% were conducted
in LMICs [2] and a review of specific types of cluster tri-
als reveal that a similar, if not greater, number of more
recent cluster trials are conducted in LMICs [3]. While
there is a growing literature on the ethics of CRTs, [4–7]
few articles deal specifically with ethical issues arising in
LMIC settings [8–11]. In this article, we discuss ethical
issues in two LMIC case studies, the PolyIran trial (Iran)
and the PASTAL trial (Malawi).
Compared to individually randomized designs, CRTs
are statistically inefficient and more prone to bias [1,
12]. Consequently, the choice of a cluster randomized
design must be justified [13]. Public health, health ser-
vices and health policy interventions are commonly ad-
ministered at the level of the community, health system
or hospital and, as a result, require a cluster randomized
design. In other cases, education and training may be
provided to health providers to promote evidence-based
care. Evaluating these knowledge translation interven-
tions requires a cluster design, as the patients cared for
by each physician constitute a cluster. Individual level
interventions, such as patient education, may justify the
use of a cluster randomized design to prevent contamin-
ation—although only when the risk of contamination is
high [14]. Sometimes justifications of administrative effi-
ciency or a reduction in costs are used.
CRTs also raise specific ethical challenges that differ
from individually randomized designs and complicate
the interpretation of standard research ethics guidelines
[4]. These ethical challenges include the following. First,
CRTs involve groups rather than individuals. As the
moral status of groups is often unclear, this complicates
whether permission ought to be sought on behalf of the
group, as group interests may conflict with individual in-
terests. Second, in CRTs the units of randomization,
intervention and outcome assessment may differ. This
can complicate the identification of research partici-
pants. Third, clusters may be randomized before cluster
members can be approached for informed consent for
exposure to the intervention. This can further compli-
cate the consent procedure as the role and permissions
that gatekeepers are able to provide is often misunder-
stood. Fourth, the intervention may be delivered to the
cluster as a whole, the individual, or both. As cluster
level interventions may be difficult or impossible to
avoid, this seems to render refusal of study participation
meaningless. Nonetheless, informed consent for data
collection in such cases may be required.
The Ottawa Statement on the ethical design and con-
duct of CRTs provides the first international ethics guid-
ance for CRTs [15]. The Ottawa Statement addresses
seven broad ethical issues and sets out 15 recommenda-
tions for the design and conduct of CRTs (Table 1). It
provides guidance on the justification of the use of a
cluster randomized design, the need for research ethics
committee review, the identification of research partici-
pants, obtaining informed consent, seeking gatekeeper
permission, benefit–harm analyses, and protecting vul-
nerable participants. While the Ottawa Statement is
intended to have international applicability, the authors
acknowledge that “LMIC perspectives were underrepre-
sented...[and] recommend that subsequent revisions
include greater LMIC representation” [15]. In what fol-
lows, we use the lens of the Ottawa Statement to analyze
two CRTs conducted in LMIC settings in order to iden-
tify gaps or ethical issues requiring further analysis and
guidance. The identified gaps and ethical issues will in-
form a forthcoming revision process for the Ottawa
Statement. As such, we do not seek to provide solutions
to these issues in this paper.
Case study 1
Summary of the PolyIran trial
Deaths from coronary artery disease are anticipated to
increase twofold from 1990 to 2020, and a large majority
of the increase is expected to occur in LMICs [16, 17].
Thus, strategies to prevent coronary artery disease that
are suitable for implementation in LMICs are a health
priority. The polypill concept—a fixed-dose combination
pill of established generic drugs—may simplify and pro-
vide a more acceptable treatment regimen, while pre-
venting substantial numbers of heart attacks and strokes
[18]. Furthermore, the availability of most of the polypill
components in a generic form may help to reduce its
cost, which is especially important in lower-resource set-
tings [19].
The PolyIran trial was designed to assess the effective-
ness and safety of the polypill tablet for primary and sec-
ondary prevention of cardiovascular disease (Table 2)
[20, 21]. The polypill tablet comprises four generic drugs
to reduce blood clotting, lower lipids and reduce blood
pressure (aspirin, atorvastatin, hydrochlorothiazide, and
either enalapril or valsartan). The PolyIran trial is nested
within the infrastructure of the Golestan cohort study
and will determine the value of the polypill in a real-life
setting. The Golestan cohort study was launched in
January 2004 to investigate the epidemiology of esopha-
geal cancer in participants 40–75 years old in Golestan
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province, Iran [22]. Cohort participants who lived in
rural areas and were at least 50 years old were eligible
for the PolyIran trial. Villages (clusters) were randomly
allocated to one of two arms: the polypill arm or the
augmented care arm. In each cluster, residents over the
age of 50 years were invited to receive a daily polypill
tablet and nonpharmacological preventive interventions
(polypill arm) or nonpharmacological preventive inter-
ventions alone (augmented care arm). In total, 8410 par-
ticipants were enrolled from 236 clusters, including 4233
participants (120 clusters) in the polypill arm and 4177
participants (116 clusters) in the augmented care arm.
An additional comparison will be made between the two
trial arms and Golestan cohort study members who were
Table 1 Ottawa Statement on the ethical design and conduct of cluster randomized trials: summary of recommendations
Number Ethical issue Recommendation
1 Justifying the cluster
randomized design
Researchers should provide a clear rationale for the use of the cluster randomized design and adopt
statistical methods appropriate for this design




Researchers should clearly identify the research participants in CRTs. A research participant can be identified
as an individual whose interests may be affected as a result of study interventions or data collection
procedures; that is, an individual:
1) who is the intended recipient of an experimental (or control) intervention; or
2) who is the direct target of an experimental (or control) manipulation of his/her environment; or
3) with whom an investigator interacts for the purpose of collecting data about that individual; or
4) about whom an investigator obtains identifiable private information for the purpose of collecting data
about that individual.
Unless one or more of these criteria is met, an individual is not a research participant
4 Obtaining informed consent Researchers must obtain informed consent from human research participants in a CRT, unless a waiver of
consent is granted by an REC under specific circumstances
5 When participants’ informed consent is required, but recruitment of participants is not possible before
randomization of clusters, researchers must seek participants’ consent for trial enrollment as soon as
possible after cluster randomization—that is, as soon as the potential participant has been identified, but
before the participant has undergone any study interventions or data collection procedures
6 An REC may approve a waiver or alteration of consent requirements when 1) the research is not feasible
without a waiver or alteration of consent and 2) the study interventions and data collection procedures
pose no more than minimal risk
7 Researchers must obtain informed consent from professionals or other service providers who are research
participants unless conditions for a waiver or alteration of consent are met
8 Gatekeepers Gatekeepers should not provide proxy consent on behalf of individuals in their cluster
9 When a CRT may substantially affect cluster or organizational interests, and a gatekeeper possesses the
legitimate authority to make decisions on its behalf, the researcher should obtain the gatekeeper’s
permission to enroll the cluster or organization in the trial. Such permission does not replace the need for
the informed consent of research participants
10 When CRT interventions may substantially affect cluster interests, researchers should seek to protect cluster
interests through cluster consultation to inform study design, conduct and reporting. Where relevant,
gatekeepers can often facilitate such a consultation
11 Assessing benefits and
harms
The researcher must ensure that the study intervention is adequately justified. The benefits and harms of
the study intervention must be consistent with competent practice in the field of study relevant to the CRT
12 Researchers must adequately justify the choice of the control condition. When the control arm is usual
practice or no treatment, individuals in the control arm must not be deprived of effective care or programs
to which they would have access were there no trial
13 Researchers must ensure that data collection procedures are adequately justified. The risks of data collection
procedures must 1) be minimized consistent with sound design and 2) stand in reasonable relation to the
knowledge to be gained
14 Protecting vulnerable
participants
Clusters may contain some vulnerable participants. In these circumstances, researchers and RECs must
consider whether additional protections are needed
15 When individual informed consent is required, and there are individuals who may be less able to choose
participation freely because of their position in a cluster or organizational hierarchy, RECs should pay special
attention to recruitment, privacy and consent procedures for those participants
CRT cluster randomized trial, REC research ethics committee
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eligible for, but not selected to participate in, the Poly-
Iran trial but who live in villages not included in the trial
(comparator cohort) [20].
The primary outcome in the PolyIran trial is the oc-
currence of major cardiovascular events within 5 years
of enrolment [20]. Outcomes will be ascertained through
the Golestan cohort study that involves collection of
these data for all cohort participants through annual
telephone contact, home visits, interview and medical
record review. Personnel who collected outcome data
were blinded to trial participation and treatment arm
allocation.
Ethical issues raised by the PolyIran trial
Justification for the use of a cluster randomized design
As cluster randomized designs are statistically inefficient
and prone to bias, their use requires justification
(Table 1). In this case, residents of the villages in north-
ern Iran have close familial relationships and residents
commonly share medicines with one another. Therefore,
the issue of contamination was a major concern. A clus-
ter randomized design in which the village was the clus-
ter was chosen to mitigate the risk of contamination
through pill sharing [20].
Obtaining informed consent from trial participants
Although the PolyIran trial is a CRT, the trial interven-
tions (polypill tablet and nonpharmacological preven-
tion) were offered to all village residents over the age of
50 years. As the study intervention is delivered at the
level of the individual, the trial is an individual-cluster
trial. In individual-cluster trials, it is typically feasible to
obtain the informed consent of participants. Thus, in the
PolyIran trial, informed consent was obtained for the
polypill and augmented care interventions and use of
outcome data.
The high illiteracy rate in the study population (almost
80%) [22] presented a challenge to obtaining informed
consent. Research staff who are native Turkmen
speakers were trained to obtain informed consent, pro-
vided information verbally to participants, and answered
any questions. Research staff then documented the dis-
closure and the participant’s consent (or refusal) to par-
ticipation in the PolyIran trial.
Members of the Golestan cohort study provided in-
formed consent for the collection and use of data within
the cohort study, but they did not provide consent for
their data to be used in the PolyIran trial. Consequently,
Golestan study cohort members who were randomly se-
lected for the comparator cohort neither provided their
Table 2 Summary of the key characteristics of the PolyIran trial and PASTAL trial
PolyIran trial PASTAL trial
Setting Golestan province, Iran Malawi
Design Parallel-arm, individual-cluster trial Adaptive, parallel, multiarm, two-stage, individual-cluster trial
Design justification Avoid contamination Administrative and logistical reasons
Number of clusters 236 villages Stage 1: 36 antenatal clinic care days
Stage 2: 35 antenatal clinic care days
Number of
participants




1:1 ratio 1:1:1:1:1:1 ratio in stage 1
Data collection
procedures
Data collected as part of Golestan cohort study Review of health records, interviews
Experimental
intervention
Polypill plus nonpharmacological prevention Two oral HIV self-test kits only, or two oral HIV self-test kits with an offer
of $3, $10 or lottery incentive conditional on clinic attendance, or
followed by a phone call reminder
Control intervention Nonpharmacological prevention alone Invitation letter to the male partner offering HIV testing
Primary outcome Major cardiovascular events Proportion of male partners who underwent testing for HIV, regardless
of serostatus, and linked to clinic for HIV treatment or prevention
within 28 days
REC review Tehran University of Medical Sciences Research
Ethics Committee
London School of Hygiene & Tropical Medicine Ethics Committee and
College of Medicine Research Ethics Committee
Gatekeepers Local health care workers (Behvarz), local religious
leaders
Local district health officer, health clinic in-charge
Consent model Verbal informed consent with documentation Written informed consent from women; waiver of consent for male
partners
REC research ethics committee
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permission nor were they aware that their data were to
be used in the PolyIran trial. While the outcome data
collection was identical between the two studies, both
studies have differing purposes and objectives. After de-
liberation, the research ethics committee responsible for
the PolyIran study concluded that no additional consent
was required from Golestan study cohort members to
use their outcome data in the PolyIran trial.
Dealing with current clinical practice in the study
population
As with many trials conducted in LMICs, recruitment
for the PolyIran trial was not undertaken in conjunction
with the participants’ primary or secondary care phys-
ician, but rather through a separate and study-specific
group of physicians. Some participants were already re-
ceiving treatment for cardiovascular disease. For control
arm participants, their medications were recorded. How-
ever, for intervention arm participants, the researchers
sent a letter to patients’ physicians explaining the trial
and the composition of the polypill tablet. In case of
medication duplication, physician were asked to adjust
participants’ prescribed medications accordingly. All
changes to medications were recorded for future follow-
up and analysis.
Post-trial access to the study interventions
It is widely acknowledged that, particularly in an LMIC
setting, participants should have access to a trial inter-
vention when it is found to be effective [23]. In the Poly-
Iran trial, if the polypill is shown to be safe and effective,
it is anticipated that it will be provided to participants in
the polypill and augmented care trial arms for 5 years.
However, for how long should the polypill tablet be pro-
vided to participants at the expense of the researchers
and sponsor? Naturally, there are concerns regarding
feasibility of this decision for long-term access.
Added complications follow when considering the
issue of whether members of the Golestan cohort study
selected for the comparator cohort should be provided
with the study intervention should it be found to be ef-
fective. Not only does this have larger resource and cost
implications, but also as their informed consent for data
use in the PolyIran trial was not obtained, comparator
cohort participants were not aware of the trial. It was
decided that members of the comparator cohort would
not be provided with the polypill tablet after completion
of the trial.
Research ethics committee review
Consistent with other international ethics documents,
the Ottawa Statement requires that all CRTs be submit-
ted to a research ethics committee (Table 1). The Poly-
Iran trial was reviewed and approved by the research
ethics committee of the Digestive Diseases Research In-
stitute at the Tehran University of Medical Sciences in
Iran. In its review, the research ethics committee did not
refer to the Ottawa Statement. However, the research
ethics committee had reviewed CRTs before and is
knowledgeable about cluster randomized designs.
Case study 2
Summary of the PASTAL trial
Each year, 1.1 million people die from human immuno-
deficiency virus (HIV) infection worldwide and 1.9 mil-
lion people become infected, the majority of whom
reside in LMICs [24]. However, little over half of people
living with HIV are aware of their HIV status, while
many of those who know their status do not start anti-
retroviral therapy [24]. The benefits of timely initiation
of antiretroviral therapy [25] and effective HIV preven-
tion, including voluntary medical male circumcision,
[26–29] have changed the emphasis of HIV testing ser-
vices from learning one’s status to appropriate linkage to
care or prevention and retention [24]. However, uptake
of HIV testing services and linkage into care or preven-
tion remains below current targets in most LMICs [30,
31]. Major barriers to HIV testing include lack of confi-
dentiality, costs incurred by users, and lack of perceived
benefits from accessing HIV testing services [32–36].
The use of financial incentives has been shown to in-
crease the uptake of HIV testing [37, 38] but with mixed
results for linkage to post-test services in different set-
tings [39–41].
Building on the successes of HIV self-testing in other
populations, [42, 43] the Partner-provided Self-Testing
and Linkage (PASTAL) trial was designed to investigate
the effect of interventions to increase the uptake of HIV
testing and linkage to care or prevention among male
partners of pregnant women. PASTAL was a parallel,
multiarm, multistage CRT (Table 2). Initial
randomization was to six trial arms. The usual care arm
involved an invitation letter to the male partner offering
HIV testing sent via a pregnant partner accessing ante-
natal care for the first time. Five intervention arms pro-
vided: 1) a self-test kit only; 2) a self-test kit plus a $3
incentive; 3) a self-test kit plus a $10 incentive; 4) a self-
test kit plus a lottery to receive $3; and 5) a self-test kit
plus a phone call reminder. The cluster was the ante-
natal care clinic day (e.g., Monday, Tuesday), chosen on
the basis of how antenatal care services are structured.
The trial randomized 36 clusters in the first stage in
which 93% (1007/1084) of eligible women were recruited
between August and November 2016. An independent
set of 35 clusters were randomized for the second stage
with 97% (1236/1275) of eligible women recruited be-
tween January and May 2017. The two-stage design
allowed a predefined interim analysis followed by
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predefined changes to the trial design including sample size
recalculation and dropping poor-performing trial arms.
The primary outcome was the proportion of male partners
who underwent testing for HIV (regardless of serostatus)
and who were followed up in a clinic for HIV treatment or
prevention within 28 days. Male partner clinic attendance
meant achievement of the primary outcome, with follow-
up in-person interview with women used to measure sec-
ondary outcomes including adverse events.
Ethical issues raised by the PASTAL trial
Justification of the use of an adaptive cluster randomized
design
The study interventions (letters, self-test kits and finan-
cial incentives) are administered at the level of the indi-
vidual and thus, in principle, an individually randomized
trial is possible. However, for administrative and logis-
tical reasons, and concerns over contamination, a cluster
randomized design was preferred [44].
Obtaining informed consent from trial participants
Although the PASTAL trial is a CRT, the unit of inter-
vention is the individual. Accordingly, the written in-
formed consent of all female participants was obtained.
On each day of recruitment, trial staff provided women
attending the antenatal care clinic with general informa-
tion about the trial. The intervention to which the ante-
natal care clinic day had been randomized was not
disclosed to the woman. After women completed their
antenatal care visit, they met one-on-one with a trial
staff member who screened them for eligibility and com-
pleted the informed consent process and disclosed the
trial arm.
While male partners of the female participants were
the direct targets of the intervention, their consent to
participate was not obtained. A waiver of consent for
male participants was sought and granted by the re-
search ethics committee. The waiver of consent was
sought for logistical reasons (male partners typically did
not accompany women to the antenatal clinic) and sci-
entific reasons (willingness to consent was thought to be
correlated with subsequent clinic attendance, the pri-
mary outcome measure). A number of concerns might
be raised about this approach. First, it compromises the
autonomy of male partners. Second, it may pose a risk
to women in the study if male partners discover they
were enrolled without their consent, as the prevalence of
intimate partner violence is high in the region [45].
Having conducted an interim analysis that showed the
usual care arm to be suboptimal, was there equipoise to
justify continuation to the second stage of the trial?
The original sample size calculation assumed that the
usual care arm would have 25% of male partners
achieving testing for HIV [46]. The analysis at the end of
stage one revealed this proportion in the usual care arm
was just 13%. Given that so few men in the usual care
arm were undergoing HIV testing, data safety and moni-
toring board members debated whether the usual care
should be carried forward to the second stage or
dropped. The need to include a usual care arm is a con-
tentious issue not only in adaptive trial designs; not in-
cluding a usual care arm would mean the trial would be
unable to provide a direct comparison to the care pro-
vided routinely outside of the trial, limiting its applic-
ability to the local population.
Post-trial access to study interventions
In the past 10 years, there has been considerable interest
in behavioral economics interventions, such as financial
incentives, to improve HIV outcomes [47]. The PASTAL
trial found that only the two fixed financial incentive in-
terventions of $3 and $10 significantly improved the pri-
mary outcome. However, local policy makers remain
unwilling to scale up these programs despite the strong
evidence in favor of their effectiveness. This raises the
question of sustainability or indeed whether there is so-
cial value in conducting trials with these types of inter-
ventions in contexts where routine implementation
cannot be guaranteed. To what degree a trial must begin
with assurances that effective interventions will be im-
plemented is a question requiring further reflection and
guidance.
Research ethics committee review
The PASTAL trial was reviewed and approved by the
College of Medicine Research Ethics Committee in
Malawi, and the London School of Hygiene & Tropical
Medicine Ethics Committee in London, UK. In their re-
views, neither research ethics committee referred to the
Ottawa Statement. However, both research ethics com-
mittees have reviewed CRTs previously and are
knowledgeable about cluster randomized designs.
Discussion
The Ottawa Statement on the ethical design and con-
duct of CRTs provides ethical guidance for CRTs but
does not explicitly consider issues specific to the LMIC
setting. Our ethical analysis of two case studies reveals
gaps in the Ottawa Statement and shows that further
work is required on ethical issues of CRTs in the LMIC
setting. Here we briefly highlight four issues. First,
obtaining informed consent remains a challenge in some
LMIC settings. The ethical principle of respect for per-
sons supports a general requirement that researchers ac-
quire the informed consent of research participants. In
some LMICs, however, low levels of literacy may impede
the ability of researchers to seek and obtain informed
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consent in writing [48]. In other settings, the fact that
potential participants fail to distinguish research activ-
ities from clinical care or that they possess different
health concepts poses a barrier to valid informed con-
sent [49].
In the PolyIran trial, high rates of illiteracy necessi-
tated the use of verbal consent obtained and docu-
mented by local research staff. However, issues such as
when is verbal consent acceptable and what practices
ought to be in place to ensure accurate communication
of study information and voluntary consent to study par-
ticipation remain unanswered. In the PASTAL trial,
pregnant women provided written informed consent to
study participation, but their male partners did not. Cri-
teria for a waiver of consent (socially valuable research,
minimal risk, and infeasibility with consent) require con-
siderable interpretation. How ought minimal risk be
understood (e.g., is the possibility of partner violence
consistent with minimal risk), and when is a study ‘in-
feasible’ if consent is required (e.g., lower recruitment,
additional research staff required, cost); all these require
due consideration if they are to be implemented reason-
ably and consistently.
Second, the choice of an ethically appropriate control
arm remains contentious in LMIC settings. The ethical
principle of beneficence requires that the potential bene-
fits and risks of participation stand in reasonable rela-
tion. This means, in part, that the study intervention and
control need to be consistent with equipoise. The short-
course zidovudine trial to prevent maternal–fetal trans-
mission of HIV in sub-Saharan Africa raised promin-
ently the issue of appropriate level of care for control
groups in trials conducted in LMICs [50]. Should those
in the control arm receive augmented care, care as de-
fined by national (or even international) standards, or lo-
cally available care [51]?
The PolyIran trial employed both an augmented care
arm with nonpharmacological prevention for cardiovas-
cular disease and a nonrandomized comparator cohort
who received no study interventions. The PASTAL trial
employed a usual care arm but discovered at a planned
interim analysis that local care was producing very poor
results in terms of follow-up testing of male partners
(13% compared to an expected 25%). The issue of locally
available care versus care mandated by national or inter-
national standards is an especially pressing issue in
CRTs of implementation interventions. In order to ob-
tain evidence that an intervention will improve care at
the local level, locally available care is needed as the
comparator group.
Third, post-trial access is an important issue for CRTs
in LMIC settings. The ethical principle of justice re-
quires that the burdens and benefits of study participa-
tion ought to be distributed equitably. Post-trial access
to study interventions that are proven effective is par-
ticularly important in LMIC settings [52]. The Ottawa
Statement says that research ethics committees “should
consider whether and when the control clusters will re-
ceive the study intervention if the study intervention is
shown to be effective” [15]. More recent guidance from
the Council for International Organizations of Medical
Sciences requires researchers and sponsors to “make
every effort, in cooperation with government and other
relevant stakeholders, to make available as soon as pos-
sible any intervention or product developed, and know-
ledge generated, for the population or community in
which the research is carried out” [23].
However, further guidance is required. The PolyIran
trial raises the issue of how broadly post-trial access
should be conceived—to trial participants only or all
those who contributed data to the analysis? The PAS-
TAL trial highlights the difficulty of ensuring access to
effective interventions after the trial.
Fourth, there is a pressing need for ethics education
and capacity building regarding CRTs in LMIC settings.
The need for capacity building and education in research
ethics in LMICs has been recognized for some years.
Millum and colleagues observe that:
Global health research will not thrive without a
knowledgeable global discussion of the ethics of the
research to shape its course. Given the expected fur-
ther increases in the health research hosted by
LMICs, more capacity will have to be built in order
to ensure that human subjects protections are main-
tained even at present levels… Neglected disease trials
in disease-endemic countries pose particularly difficult
ethical challenges [53].
Innovative or unfamiliar trial designs also pose ethical
challenges for researchers and research ethics commit-
tees in LMICs. CRTs are increasingly used in LMICs
and they raise issues that complicate the interpretation
of standard ethics guidelines.
While the Ottawa Statement on the ethical design and
conduct of CRTs provides useful guidance, [15] the re-
search ethics committees reviewing the PolyIran and
PASTAL trials did not refer to the document. In our ex-
perience, the Ottawa Statement is not widely known or
used within LMICs. Thus, education on ethics issues in
CRTs and available guidance is a priority for health re-
search in LMICs. Web-based educational materials on
the ethics of CRTs with LMIC examples would provide
a widely accessible resource. Regional workshops for re-
searchers and research ethics committees would provide
the opportunity for deeper discussion of issues and
learning. Finally, training fellowships would allow re-
searchers and ethics committee members the opportun-
ity to develop specific projects with internationally
recognized experts.
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Conclusion
Our ethical analysis of the PolyIran and PASTAL trials
reveals gaps in the Ottawa Statement and shows that
further work is required on ethical issues of CRTs in the
LMIC setting.
First, standards for verbal consent and waivers of con-
sent require methods for operationalization if they are to
be employed consistently. Second, the appropriate
choice of a control arm remains contentious, and the ac-
ceptability of locally available care as the comparator in
implementation CRTs, especially when such care falls
below national standards, should be assessed. Third, as it
is often not possible to guarantee post-trial access to
study interventions, clarity on stakeholder obligations is
needed. Fourth, there is a pressing need for ethics edu-
cation and capacity building on CRTs. These identified
gaps and ethical issues will inform a forthcoming revi-
sion process for the Ottawa Statement.
Abbreviations
CRT: Cluster randomized trial; HIV: Human immunodeficiency virus;
LMIC: Low- and middle-income country
Acknowledgements
The authors thank A. Belardo for editing the manuscript.
About this supplement
This article has been published as part of Trials Volume 21 Supplement 1,
2020: The ethics of alternative clinical trial designs and methods in LMIC




ATC, GR and CW conceived this article and drafted the manuscript. All
authors commented on drafts of the manuscript and approved the final
manuscript.
Funding
Funds were provided by the Global Forum for Bioethics in Health Research.
Funds were also provided by a Canadian Institute of Health Research grant
(JT–153045). ATC is funded by Wellcome Trust and National Institute for
Health Research as an International Intermediate Fellow (216458/Z/19/Z). KH
holds an NIHR Senior Research Fellowship (SRF-2017-002).





ATC was principal investigator for the PASTAL trial. RM and GR were principal
investigators for the PolyIran trial. CW receives consulting income from Eli
Lilly and Company. The remaining authors declare that they have no
competing interests.
Author details
1Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre,
Malawi. 2Department of Infectious Disease Epidemiology, London School of
Hygiene and Tropical Medicine, London, UK. 3Golestan Research Center of
Gastroenterology and Hepatology, Golestan University of Medical Sciences,
Gorgan, Iran. 4Department of Health Promotion, Education and Behaviour,
University of South Carolina, Columbia, USA. 5Department of Clinical
Research, London School of Hygiene and Tropical Medicine, London, UK.
6School of Public Health, University of the Witwatersrand, Johannesburg,
South Africa. 7Institute of Applied Health Research, University of Birmingham,
Birmingham, UK. 8Digestive Disease Research Center, Digestive Diseases
Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
9Rotman Institute of Philosophy, Western University, London, Canada.
Published: 16 April 2020
References
1. Donner A, Klar N. Design and analysis of cluster randomization trials in
health research. London: Arnold; 2000.
2. Taljaard M, McRae AD, Weijer C, Bennett C, Dixon S, Taleban J, Skea Z,
Eccles MP, Brehaut JC, Donner A, Saginur R, Boruch RF, Grimshaw JM.
Inadequate reporting of research ethics review and informed consent in
cluster randomised trials: review of random sample of published trials. BMJ.
2011;342:d2496.
3. Martin J, Taljaard M, Girling A, Hemming K. Systematic review finds major
deficiencies in sample size methodology and reporting for stepped-wedge
cluster randomised trials. BMJ Open. 2016;6(2):e010166.
4. Weijer C, Grimshaw JM, Taljaard M, Binik A, Boruch R, Brehaut JC, Donner A,
Eccles MP, Gallo A, McRae AD, Saginur R, Zwarenstein M. Ethical issues
posed by cluster randomized trials in health research. Trials. 2011;12:100.
5. Sim J, Dawson A. Informed consent and cluster randomized trials. Am J
Public Health. 2012;102(3):480–5.
6. Edwards SJ, Braunholtz DA, Lilford RJ, Stevens AJ. Ethical issues in the
design and conduct of cluster randomised controlled trials. BMJ. 1999;
318(7195):1407–9.
7. Hutton JL. Are distinctive ethical principles required for cluster randomized
controlled trials? Stat Med. 2001;20(3):473–88.
8. Osrin D, Azad K, Fernandez A, Manandhar DS, Mwansambo CW, Tripathy P,
Costello AM. Ethical challenges in cluster randomized controlled trials:
experiences from public health interventions in Africa and Asia. Bull World
Health Organ. 2009;87(10):772–9.
9. Ledogar RJ, Hernández-Alvarez C, Morrison AC, Arosteguí J, Morales-Perez A,
Nava-Aguilera E, Legorreta-Soberanis J, Caldwell D, Coloma J, Harris E,
Andersson N. When communities are really in control: ethical issues
surrounding community mobilisation for dengue prevention in Mexico and
Nicaragua. BMC Public Health. 2017;17(Suppl 1):410.
10. Kass NE, DeLuca AN, Coetzee L, Simwinga M, Churchyard GJ, Ayles H,
Beyers N, Godfrey-Faussett P, Durovni B, Chaisson RE, Eldred LJ. Applying
ethical principles to international community-based research: a case study
from the Consortium to Respond Effectively to the AIDS-TB Epidemic
(CREATE). IRB. 2014;36(3):1–8.
11. Mtande TK, Weijer C, Hosseinipour MC, Taljaard M, Matoga M, Goldstein CE,
Nyambalo B, Rosenberg NE. Ethical issues raised by cluster randomised trials
conducted in low-resource settings: identifying gaps in the Ottawa
Statement through an analysis of the PURE Malawi trial. J Med Ethics. 2019;
45(6):388–93.
12. Puffer S, Torgerson D, Watson J. Evidence for risk of bias in cluster
randomised trials: review of recent trials published in three general medical
journals. BMJ. 2003;327(7418):785–9.
13. Taljaard M, Weijer C, Grimshaw JM, Eccles MP, Ottawa Ethics of Cluster
Randomised Trials Consensus Group. The Ottawa Statement on the ethical
design and conduct of cluster randomised trials: précis for researchers and
research ethics committees. BMJ. 2013;346:f2838.
14. Torgerson DJ. Contamination in trials: is cluster randomisation the answer?
BMJ. 2001;322(7282):355–7.
15. Weijer C, Grimshaw JM, Eccles MP, McRae AD, White A, Brehaut JC, Taljaard
M, Ottawa Ethics of Cluster Randomized Trials Consensus Group. The
Ottawa Statement on the ethical design and conduct of cluster randomized
trials. PLoS Med. 2012;9(11):e1001346.
16. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A
comparative risk assessment of burden of disease and injury attributable to
67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic
analysis for the Global Burden of Disease Study 2010. Lancet. 2012;
380(9859):2224–60.
17. World Health Organization (WHO). Non-communicable diseases (2012).
http://www.who.int/gho/ncd/en/index.html. Accessed: 24 January 2020.
18. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than
80%. BMJ. 2003;326(7404):1419.
19. Reddy KS. The preventive polypill—much promise, insufficient evidence. N
Engl J Med. 2007;356(3):212.
Choko et al. Trials 2020, 21(Suppl 1):314 Page 8 of 9
20. Ostovaneh MR, Poustchi H, Hemming K, Marjani H, Pourshams A, Nateghi A,
Majed M, Navabakhsh B, Khoshnia M, Jaafari E, Mohammadifard N,
Malekzadeh F, Merat S, Sadeghi M, Naemi M, Etemadi A, Thomas GN,
Sarrafzadegan N, Cheng KK, Marshall T, Malekzadeh R. Polypill for the
prevention of cardiovascular disease (PolyIran): study design and rationale
for a pragmatic cluster randomized controlled trial. Eur J Prev Cardiol. 2015;
22(12):1609–17.
21. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A,
Rastegarpanah M, Khoshnia M, Semnani S, Salahi R, Thomas GN, Larijani B,
Cheng KK, Malekzadeh R. A pilot double-blind randomised placebo-
controlled trial of the effects of fixed-dose combination therapy ('polypill')
on cardiovascular risk factors. Int J Clin Pract. 2010;64(9):1220–7.
22. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR,
Jafari E, Rakhshani N, Salahi R, Semnani S, Kamangar F, Abnet CC, Ponder B,
Day N, Dawsey SM, Boffetta P, Malekzadeh R. Cohort profile: the Golestan
Cohort Study—a prospective study of oesophageal cancer in northern Iran.
Int J Epidemiol. 2010;39(1):52–9.
23. Council for International Organizations of Medical Sciences. International
ethical guidelines for health-related research involving humans. 2016.
https://cioms.ch/shop/product/international-ethical-guidelines-for-health-
related-research-involving-humans/. Accessed: 24 January 2020.
24. World Health Organization. Progress report 2016: prevent HIV, test and treat
all. Geneva: WHO; 2016.
25. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser
O, Fox MP, Wood R, Prozesky H, Giddy J, Garone DB, Cornell M, Egger M,
Boulle A, International Epidemiologic Databases to Evaluate AIDS Southern
Africa Collaboration. Life expectancies of South African adults starting
antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med.
2013;10(4):e1001418.
26. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka
N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-
Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O,
Quinn TC, Wawer MJ. Male circumcision for HIV prevention in men in Rakai,
Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.
27. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C,
Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN,
Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004
Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral
microbicide, for the prevention of HIV infection in women. Science. 2010;
329(5996):1168–74.
28. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary
HIV testing with immediate antiretroviral therapy as a strategy for
elimination of HIV transmission: a mathematical model. Lancet. 2009;
373(9657):48–57.
29. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea
P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O,
Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M,
Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance
RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee
J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, iPrEx Study Team.
Preexposure chemoprophylaxis for HIV prevention in men who have sex
with men. N Engl J Med. 2010;363(27):2587–99.
30. UNAIDS. 90–90-90: an ambitious treatment target to help end the AIDS
epidemic. Geneva: UNAIDS; 2014.
31. World Health Organization. Global update on the health sector response to
HIV, 2014. Geneva: WHO; 2014.
32. Kalichman SC, Simbayi LC. HIV testing attitudes, AIDS stigma, and voluntary
HIV counselling and testing in a black township in Cape Town, South Africa.
Sex Transm Infect. 2003;79(6):442–7.
33. Wolff B, Nyanzi B, Katongole G, Ssesanga D, Ruberantwari A, Whitworth J.
Evaluation of a home-based voluntary counselling and testing intervention
in rural Uganda. Health Policy Plan. 2005;20(2):109–16.
34. Morin SF, Khumalo-Sakutukwa G, Charlebois ED, Routh J, Fritz K, Lane T, Vaki T,
Fiamma A, Coates TJ. Removing barriers to knowing HIV status: same-day mobile
HIV testing in Zimbabwe. J Acquir Immune Defic Syndr. 2006;41(2):218–24.
35. Wringe A, Roura M, Urassa M, Busza J, Athanas V, Zaba B. Doubts, denial
and divine intervention: understanding delayed attendance and poor
retention rates at a HIV treatment programme in rural Tanzania. AIDS Care.
2009;21(5):632–7.
36. Angotti N, Bula A, Gaydosh L, Kimchi EZ, Thornton RL, Yeatman SE.
Increasing the acceptability of HIV counseling and testing with three
C's: convenience, confidentiality and credibility. Soc Sci Med. 2009;
68(12):2263–70.
37. Thornton RL. The demand for, and impact of, learning HIV status. Am Econ
Rev. 2008;98(5):1829–63.
38. Kranzer K, Simms V, Bandason T, Dauya E, McHugh G, Munyati S, Chonzi P,
Dakshina S, Mujuru H, Weiss HA, Ferrand RA. Economic incentives for HIV
testing by adolescents in Zimbabwe: a randomised controlled trial. Lancet
HIV. 2018;5(2):e79–86.
39. Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS,
Balakrishnan P, Mehta SH, Solomon S, Lucas GM. Voucher incentives
improve linkage to and retention in care among HIV-infected drug users in
Chennai, India. Clin Infect Dis. 2014;59(4):589–95.
40. El-Sadr WM, Donnell D, Beauchamp G, Hall HI, Torian LV, Zingman B, Lum G,
Kharfen M, Elion R, Leider J, Gordin FM, Elharrar V, Burns D, Zerbe A, Gamble
T, Branson B, HPTN 065 Study Team. Financial incentives for linkage to care
and viral suppression among hiv-positive patients: a randomized clinical trial
(HPTN 065). JAMA Intern Med. 2017;177(8):1083–92.
41. Maughan-Brown B, Smith P, Kuo C, Harrison A, Lurie MN, Bekker LG,
Galárraga O. A conditional economic incentive fails to improve linkage to
care and antiretroviral therapy initiation among HIV-positive adults in Cape
Town, South Africa. AIDS Patient Care STDS. 2018;32(2):70–8.
42. Choko AT, Desmond N, Webb EL, Chavula K, Napierala-Mavedzenge S,
Gaydos CA, Makombe SD, Chunda T, Squire SB, French N, Mwapasa V,
Corbett EL. The uptake and accuracy of oral kits for HIV self-testing in high
HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi.
PLoS Med. 2011;8(10):e1001102.
43. Choko AT, MacPherson P, Webb EL, Willey BA, Feasy H, Sambakunsi R,
Mdolo A, Makombe SD, Desmond N, Hayes R, Maheswaran H, Corbett EL.
Uptake, accuracy, safety, and linkage into care over two years of promoting
annual self-testing for HIV in Blantyre, Malawi: a community-based
prospective study. PLoS Med. 2015;12(9):e1001873.
44. Hayes JR, Moulton LH. Cluster randomised trials. Boca Raton, USA: Chapman
and Hall/CRC; 2009.
45. Shamu S, Abrahams N, Temmerman M, Musekiwa A, Zarowsky C. A
systematic review of African studies on intimate partner violence against
pregnant women: prevalence and risk factors. PLoS One. 2011;6(3):e17591.
46. Nyondo AL, Choko AT, Chimwaza AF, Muula AS. Invitation cards during
pregnancy enhance male partner involvement in prevention of mother to
child transmission (PMTCT) of human immunodeficiency virus (HIV) in
Blantyre, Malawi: a randomized controlled open label trial. PLoS One. 2015;
10(3):e0119273.
47. Zullo AR, Caine K, Galarraga O. The dollars and sense of economic
incentives to modify HIV-related behaviours. J Int AIDS Soc. 2015;18(1):
20724.
48. Tindana PO, Kass N, Akweongo P. The informed consent process in a rural
African setting: a case study of the Kassena-Nankana district of northern
Ghana. IRB. 2006;28:1–6.
49. Molyneux CS, Wassenaar DR, Peshu N, Marsh K. 'Even if they ask you to
stand by a tree all day, you will have to do it (laughter)…!': community
voices on the notion and practice of informed consent for biomedical
research in developing countries. Soc Sci Med. 2005;61(2):443–54.
50. Angell M. The ethics of clinical research in the third world. N Engl J Med.
1997;337(12):847–9.
51. London AJ. The ambiguity and the exigency: clarifying 'standard of care'
arguments in international research. J Med Philos. 2000;25(4):379–97.
52. Dal-Ré R, Ndebele P, Higgs E, Sewankambo N, Wendler D. Protections for
clinical trials in low and middle income countries need strengthening not
weakening. BMJ. 2014;349:g4254.
53. Millum J, Grady C, Keusch G, Sina B. Introduction: the Fogarty International
Research Ethics Education and Curriculum Development Program in
historical context. J Empir Res Hum Res Ethics. 2013;8(5):3–16.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Choko et al. Trials 2020, 21(Suppl 1):314 Page 9 of 9
